Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Profound Medical Corp.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Profound Medical Corp. (“Profound” or “the Company”) (NASDAQ: PROF). Investors who purchased Profound securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Profound has violated federal securities laws.
Investigation Details
On March 7, 2025, Profound disclosed in an SEC filing that “the Company identified an error which overstated revenue by $472,000 in the first quarter of 2024.” Profound admitted that its quarterly reports for the first three quarters of 2024 could no longer be relied upon by investors. Following this news, Profound stock dropped around 5.9% on that same day.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Profound securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
PROF — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”